WEST CHESTER, Ohio, April 18 AtriCure, Inc.(Nasdaq: ATRC), a medical device company and a leader in cardiac surgicalablation products, will release its financial results for the first quarterended March 31, 2008 on Tuesday, May 6, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, May 6,2008 to discuss first quarter 2008 results. A live web cast of the conferencecall will be available online from the investor relations page of AtriCure'scorporate web site at www.atricure.com.
Pre-registration is available for this call at the following URL:
Pre-registering is not mandatory but is recommended as it will provide youimmediate entry into the call and will facilitate the timely start of theconference. Pre-registration only takes a few moments and you may pre-registerat any time, including up to and after the call start time. Alternatively, ifyou prefer being placed into the call by an operator, please call(888) 713-4215 for domestic callers and (617) 213-4867 for internationalcallers at least 15 minutes prior to the call start time and use reservationnumber 74210586.
The web cast will remain available on AtriCure's web site through June 6,2008. A telephonic replay of the call will also be available until June 6,2008. The replay dial-in numbers are (888) 286-8010 for domestic callers and(617) 801-6888 for international callers. Please use reservation code90053061.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,manufacturing and selling innovative cardiac surgical ablation systemsdesigned to create precise lesions, or scars, in cardiac, or heart, tissue.Medical journals have described the adoption by leading cardiothoracicsurgeons of the AtriCure Isolator(R) bipolar ablation system as a treatmentalternative during open-heart surgical procedures to create lesions in cardiactissue to block the abnormal electrical impulses that cause atrialfibrillation, or AF, a rapid, irregular quivering of the upper chambers of theheart. Additionally, medical journals and leading cardiothoracic surgeons havedescribed the AtriCure Isolator(R) system as a promising treatment alternativefor patients who may be candidates for sole-therapy minimally invasiveprocedures. AF affects more than 5.5 million people worldwide and predisposesthem to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,including its Isolator Synergy(TM) ablation clamps, and AtriCure'smultifunctional and linear ablation pens, for the ablation, or destruction, ofcardiac tissue during surgical procedures. Additionally, the FDA has clearedAtriCure's multifunctional pen for temporary pacing, sensing, stimulating andrecording during the evaluation of cardiac arrhythmias. To date, the FDA hasnot cleared or approved AtriCure's products for the treatment of AF.AtriCure's left atrial appendage clip system has not been approved forcommercial use. It is currently being used in clinical evaluations in Europe.Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 email@example.com
SOURCE AtriCure, Inc.